Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation

Summary

Recombinant human soluble thrombomodulin (rhTM) is a novel class of anticoagulants for treating disseminated intravascular coagulation (DIC). Although rhTM is widely used in clinical settings throughout Japan, there is limited clinical evidence supporting the use of rhTM in patients with sepsis-induced DIC. Furthermore, rhTM is not approved for DIC treatment in other countries. This study aimed to clarify the survival benefits of rhTM administration in critically ill patients. Data from 3,195 consecutive adult patients who were admitted to 42 intensive care units for the treatment of severe sepsis or septic shock between January 2011 and December 2013 were retrospectively analysed, and 1,784 patients were diagnosed with DIC based on the scoring algorithm from the Japanese Association for Acute Medicine DIC (n = 645, rhTM group; n = 1,139, control group). Propensity score matching created 452 matched pairs, and logistic regression analysis revealed a significant association between rhTM administration and lower in-hospital all-cause mortality in the propensity score-matched groups (odds ratio, 0.757; 95 % confidence interval, 0.574–0.999, p = 0.049). Inverse probability of treatment weighted and quintile-stratified analyses also revealed significant associations between rhTM administration and lower in-hospital all-cause mortality. Survival time in the propensity score-matched rhTM group was significantly longer than that in the propensity score-matched control group (hazard ratio, 0.781; 95 % confidence interval, 0.624–0.977, p = 0.03). Bleeding complications were not more frequent in the rhTM groups. In conclusion, this study demonstrated that rhTM administration is associated with reduced in-hospital all-cause mortality among patients with sepsis-induced DIC.

Keywords

Sepsis - disseminated intravascular coagulation - coagulation abnormality - mortality - thrombomodulin

• References

• 1 Weiler H. Regulation of inflammation by the protein C system. Crit Care Med 2010; 38: S18-25.
• 2 Saito H, Maruyama I, Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 05: 31-41.
• 3 Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 2014; 12: 1010-1019.
• 4 Wada H, Japanese Society, of Thrombosis, Hemostasis DICs, Okamoto K. et al. Addition of recommendations for the use of recombinant human thrombomodulin to the “Expert consensus for the treatment of disseminated intravascular coagulation in Japan”. Thromb Res 2014; 134: 924-925.
• 5 Wada H, Asakura H, Okamoto K. et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125: 6-11.
• 6 Wada H, Thachil J, Di Nisio M. et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 716-767.
• 7 Aikawa N, Shimazaki S, Yamamoto Y. et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011; 35: 349-354.
• 8 Yamakawa K, Fujimi S, Mohri T. et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011; 15: R123.
• 9 Yamakawa K, Ogura H, Fujimi S. et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013; 39: 644-652.
• 10 Tagami T, Matsui H, Fushimi K. et al. Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation. Front Med (Lausanne) 2015; 02: 7.
• 11 Tagami T, Matsui H, Horiguchi H. et al. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2015; 13: 31-40.
• 12 Vincent JL, Ramesh MK, Ernest D. et al. A randomized, double-blind, placebocontrolled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41: 2069-2079.
• 13 Yamakawa K, Aihara M, Ogura H. et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13: 508-519.
• 14 Phase 3 safety and efficacy study of ART-123 in subjects with severe sepsis and coagulopathy. Available at: http://clinicaltrialsgov/ct2/show/ NCT01598831?term=ART-123&rank=2 Accessed February 3, 2016.
• 15 Levy MM, Fink MP, Marshall JC. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
• 16 Knaus WA, Draper EA, Wagner DP. et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
• 17 Vincent JL, de Mendonca A, Cantraine F. et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-1800.
• 18 Bone RC, Balk RA, Cerra FB. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
• 19 Gando S, Iba T, Eguchi Y. et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34: 625-631.
• 20 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-1258.
• 21 Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008; 27: 2037-2049.
• 22 Lin DY, Wei LJ. The Robust Inference for the Cox Proportional Hazards Model. J Am Stat Assoc 1989; 84: 1074-1078.
• 23 Ho D, Imai K, King G. et al. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference Polit Anal. 2007; 15: 199-236.
• 24 Ho D, Imai K, King G. et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J Stat Softw. 2011 42.
• 25 Dellinger RP, Levy MM, Rhodes A. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
• 26 Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
• 27 Gando S, Saitoh D, Ogura H. et al. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care 2013; 17: R111.
• 28 Yoshimura J, Yamakawa K, Ogura H. et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care 2015; 19: 78.
• 29 Mohri M. ART-123: Recombinant Human Soluble Thrombomodulin. Cardiovasc Drug Rev 2000; 18: 312-325.
• 30 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352.
• 31 Kaiser B, Jeske W, Hoppensteadt DH. et al. In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. Thromb Res 1997; 87: 197-204.
• 32 Hayakawa M, Yamamoto H, Honma T. et al. Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment. Shock 2012; 37: 569-573.
• 33 Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011; 09 (Suppl. 01) 168-173.
• 34 Ueda T, Higashiyama M, Narimatsu K. et al. Recombinant Thrombomodulin Modulates Murine Colitis Possibly via High-Mobility Group Box 1 Protein Inhibition. Digestion 2015; 92: 108-119.
• 35 Zhang Z. Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach. BMJ Open 2014; 04: e005622.